TIME FOR ASSURERS TO ACT FOR THE BENEFIT OF POLICY OWNERS

KUALA LUMPUR, March 24 (Bernama) —

Introduction

Despite calls to engage insurers privately and not moot their points through media, APHM continues airing its concerns publicly. The general public couldn’t care less about this issue. These are private matters between APHM and Insurers. As mentioned in the same article, the relationship between private hospitals and insurers is best described as symbiotic. APHM must find solutions that flourish this relationship rather than be parasitic.  

APHM proposes the formation of a joint working committee between the association and Assurers to review billing structures and ensure fair pricing of healthcare services. It is a good start, but it needs to focus its energy on the core matter, the burdening hospital charges that cause assurers to increase their prices. The billing structure and so-called fair pricing don’t solve the current problems. It is more of an academic exercise. 

APHM’s public statements call for assurers to keep cashless medical products while using patient care as a smoke screen. It is a ruse to maintain its top and bottom line, and its sincerity can be seen when it issued a statement rejecting Assurer’s proposal for private hospitals to freeze costs for three years and also for the Health Ministry to regulate the pricing of pharmaceuticals or medication during the period assurers facing premium pricing caps. 
Public Education
Since APHM is only interested in making public statements to try to arouse policyholders’ sentiments to protect their cash flow and profit margins, it is time for assurers to take steps to protect policy owners’ interests. The public is concerned about rising health premiums. They don’t understand the reasons behind it.   

Therefore, assurers need to expand their role in public education on how assurers develop their product prices. Most of the cost goes toward paying claims, distribution costs, and maintaining statutory reserves. Assurers must demonstrate how much premium is allocated to companies as their pretax profits for every ringgit of premium received. 

Public education goes a long way and will make the public understand the financial burden caused by APHM members.

Cheaper, Scalable & Customized Direct Products
Policy owners deserve access to cheaper health assurance products. Insurers can consider two critical modifiable parameters: direct distribution without going through agents and selling the product on a reimbursement basis. Distribution through agents is costly. Technology today allows companies to educate customers on product features with ease. Product distribution has greater depth today.  

Assurers can develop tier products that cover the treatment of medical risks for specific age groups. The young have a lesser risk of admission due to chronic illnesses. The sum cover can be lowered since the cost of treatment for acute illnesses and injuries is low. Employees can buy a small sum for the employed category to cover health top-up products, where the primary claim should be against the employer’s paid assurance. The top-up is used only when the primary product limits are exhausted. 

The second strategy would be reintroducing reimbursement-based products. It has dual key advantages. First, the policy owners are responsible for controlling hospital bill expenses. Coupled with BNM directives of Co-payment, policy owners would question their hospital charges. Introducing Co-pay reimbursement products is within the assurer’s rights. We cannot blame APHMs for making public statements and calling for assurers to keep cashless medical products as they know it significantly impacts their earnings. 

The third strategy is for assurers to revisit and expand the strategy they introduced in early 2000, where they formed a consortium that markets national health assurance products instead of individual company products. An industry-wide product allows the consolidation of claim data to determine the true industry burning costs. More importantly, consolidating policy owners’ data enables the industry to spread costs and introduce cheaper products. Individual assurance companies only need to focus on distribution and customer service. The focus would be on customer service. This approach would be the seed of the National Health Assurance under the assurance industry-driven National Healthcare Financing System. 

Under this approach, the competition among the assurance companies is no longer on pricing. The law of large numbers dictates and has an impact on price. However, if private hospitals continue to have the unchecked freedom to determine the charges, the proposed measures will only temporarily reprieve policy owners.   

Conclusion
In the best interest of policy owners & to protect them against increasing premiums, re-introducing reimbursement health products would be the best approach. Policy owners themselves must take the role of questioning hospital charges, which directly impacts health assurance premiums. 

Assurers must develop products that limit the benefit payment according to age, gender, pre-existing conditions and risk exposure. A young person who enjoys employer insurance coverage does not need an RM1000,000 sum of cover. Having high annual and lifetime limits promotes “medical inflation”. 

Assurers must get their act together as an industry, focus on their policy owners, ignore APHM public statements and develop a structured public education program explaining how assurers’ price their products.

21-3-2025  

Dr Mohamed Rafick Khan 
Reassurer and Assurance Industry Consultant

Dr. Mohamed Rafick is a trained physician with 12 years of experience in military medical services and over 22 years of experience in the assurance industry. He retired as the CEO of a multinational reinsurance company in 2019. Currently, he remains active as an independent international assurance industry consultant.

SOURCE: Dr Mohamed Rafick Khan 
Reassurer and Assurance Industry Consultant

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Dr Rafick 
Tel: 012 2218956
Email: drrafick@gmail.com

–BERNAMA

SBC MEDICAL GROUP HOLDINGS ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE, AESTHETIC HEALTHCARE HOLDINGS PTE. LTD, A MULTI-UNIT OWNER OF AESTHETIC TREATMENT CLINICS IN SINGAPORE

SBC to leverage operational synergies and implement growth strategies to launch into new verticals and geographies (Graphic: Business Wire)

Aesthetic Healthcare establishes bridgehead for expansion into Asia and accelerate SBC’s presence in global markets

SBC to leverage operational synergies and implement growth strategies to launch into new verticals and geographies

TOKYO, Nov 19 (Bernama-BUSINESS WIRE) — SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”, or the “Company”, or “SBC”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a definitive agreement to acquire Aesthetic Healthcare Holdings Pte. Ltd. (“AHH”), a privately-held Singapore-based company that owns and operates several brands that provide aesthetic medical treatments in an all cash transaction scheduled to close on November 13, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241117787334/en/

The acquisition by SBC of AHH marks the first step in Company’s strategy to grow its business through acquisitions, which includes plans to expand its business internationally with a primary focus on the U.S. and Asia markets. The Company believes Singapore represents the ideal hub for the further development of its brand in the region.

Strategic Rationale: A foothold to expand into Asia

Founded by Dr. Ewen Chee, a pioneer in Singapore’s aesthetic medical industry, AHH is well established in the country with a multi-brand strategy that caters to diverse customer needs. With the acquisition of AHH, SBC believes it has taken an important step toward expanding its presence in the Asian market. AHH’s portfolio consists of four brands and 21 outlets, and will be added to the SBC clinic network, strengthening its customer base in the Asian region. SBC has positioned Singapore as the core of its Asian operations and plans to leverage the high brand recognition AHH has established to promote strategic partnerships throughout Asia. The expansion of SBC’s global presence is consistent with its mission to establish leadership in the aesthetic medical industry by providing the value of beauty and health beyond national borders through innovative aesthetic medical treatments.

Strategies to Expand the Aesthetic Medicine Market by Leveraging Singapore’s Advantages
As disposable income increases in line with recent economic growth, demand for aesthetic medical treatments to maintain youth and beauty is growing rapidly. The Asian market in particular has shown remarkable growth, and currently accounts for the second largest share of the global aesthetic medical market, with an average annual growth rate of 11%*, exceeding that of any other region. Among these, Singapore is ideally positioned as a gateway to the Asian market due to its geographical and cultural advantages, and with its well-developed medical infrastructure and regulatory environment. SBC believes it is an ideal base for expanding services throughout Asia.
*Data Source: https://straitsresearch.com/report/aesthetic-medicine-market

Dr. Ewen Chee, Chief Executive Officer of Aesthetic Healthcare Holdings Pte. Ltd., said:
“We are pleased to announce that our clinic group has become a member of SBC, one of the leading aesthetic medical clinic groups in Japan. Since our establishment, we have been committed to providing the best medical treatments to each and every patient in Singapore, and have earned the trust of many customers. We would like to express our deepest gratitude to our employees and patients for their support. We see this acquisition as an opportunity for new growth, and we are confident that SBC’s advanced technology, management know-how, and extensive experience in the Japanese market will contribute greatly to our further development. We expect to accelerate our expansion throughout Asia and provide the best aesthetic medical treatments to as many patients as possible. We also hope to contribute to the expansion of the franchise business in the U.S. by utilizing the franchise business know-how we have cultivated through the operation of SkinGo! Together, with SBC, we aim to be a leader in the Asian aesthetic medicine industry and will make further efforts to meet the expectations of each and every patient.”

Yoshiyuki Aikawa
Founder and Chief Executive Officer of SBC Medical Group Holdings, Inc., said:
“We are very pleased to welcome AHH to our group. AHH has been providing high-quality aesthetic medical services in Singapore for many years and has earned the trust of many customers. With this acquisition, we expect to accelerate our expansion into the Asian market and strengthen our global aesthetic medical treatment delivery system. We are confident that we can create significant synergies by combining expertise in aesthetic medical treatments and management know-how we have cultivated in Japan with AHH’s brand power and customer base. We intend to grow together while respecting the corporate culture that AHH has cultivated thus far. We will also respect the culture and customs of Singapore and try to manage the company in a way that is rooted in the local community, while actively contributing to the local community. By leveraging the strengths of both companies, we aim to become a leading aesthetic medical clinic in Asia.”

——————————————————————————————

About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.
For more information, visit https://sbc-holdings.com/

About Aesthetic Healthcare Holdings Pte. Ltd.
AHH is based in Singapore and operates aesthetic medical clinics, family clinics, and quick facial aesthetics outlets. The founder, Dr. Ewen Chee, is known as one of the pioneers in the field of aesthetic medicine in Singapore and is a co-chair of the first Asia Pacific Thread Lift Conference (APEM) and a board-certified physician by the American Academy of Aesthetic Medicine. He is a frequent speaker at international conferences and workshops, and his expertise and knowledge have been featured in numerous scientific publications.

Major brands and number of clinics:

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20241117787334/en/

Contact

SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
e-mail: ir@sbc-holdings.com

Source : SBC Medical Group Holdings Incorporated

ZENAS BIOPHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

WALTHAM, Mass, 8 Nov (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

SOURCE : Zenas BioPharma (USA) LLC